Neurocrine Biosciences, Inc. (NBIX) Investigated for Grossly Overcompensating Its Directors
Shareholder rights law firm Robbins LLP is investigating Neurocrine Biosciences (NASDAQ: NBIX) for gross overcompensation of its directors. After conducting an analysis of the director compensation of Neurocrine Therapeutics and its peer groups, we determined that Neurocrine Biosciences’ average director compensation differed from its peer groups’ by $263,605.50 for fiscal year 2018, $46,559.67 for fiscal year 2017, and $163,070.84 for fiscal year 2016.
